NEMO-binding domain peptide inhibits proliferation of human melanoma cells

Cancer Letters

Volumn 274, Issue 2, 2009, Pages 331-336

  Ianaro, Angela ^a   Tersigni, Mariaroberta ^a   Belardo, Giuseppe ^b   Martino, Silvana Di ^c   Napolitano, Maria ^c   Palmieri, Giuseppe ^d   Sini, MariaCristina ^d   Maio, Anna De ^a   Ombra, MariaNeve ^d   Gentilcore, Giuseppina ^c   Capone, Mariaelena ^c   Ascierto, MariaLibera ^c   Satriano, Rocco Alfredo ^e   Farina, Benedetta ^a   Faraone Mennella, MariaRosaria ^a   Ascierto, Paolo Antonio ^c   Ialenti, Armando ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d CNR   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Apoptosis; Melanoma; NBD peptide; NF B

Indexed keywords

I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING;

CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; HUMANS; I-KAPPA B KINASE; MELANOMA; NF-KAPPA B;

EID: 58149279456     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.038     Document Type: Article

References (20)

1. Amiri K.I., and Richmond A. Role of nuclear factor-κB in melanoma. Cancer and Metastasis Reviews 24 (2005) 301-313
2. Yang J., Amiri K.I., Burke J.R., Schmid J.A., and Richmond A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clinical Cancer Research 12 (2006) 950-960
3. McNulty S.E., DelRosario R., Cen D., Meyskens Jr. F.L., and Yang S. Comparative expression of NF-κB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Research 17 (2004) 173-180
4. Yang J., Pan W.H., Clawson G.A., and Richmond A. Systemic targeting inhibitor of kappab kinase inhibits melanoma tumor growth. Cancer Research 67 (2007) 3127-3134
5. Yamamoto Y., and Gaynor R.B. IκB kinases: key regulators of the NF-κB pathway. Trends in Biochemical Sciences 29 (2004) 72-79
6. May M.J., Marienfeld R.B., and Ghosh S. Characterization of the Ikappa B-kinase NEMO binding domain. The Journal of Biological Chemistry 277 (2002) 45992-46000
7. DiMeglio P., Ianaro A., and Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation. Arthritis and Rheumatism 52 (2005) 951-958
8. Piva R., Gianferretti P., Ciucci A., Taulli R., Belardo G., and Santoro M.G. 15-Deoxy-Δ12, 14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins. Blood 105 (2005) 1750-1758
9. Nakajima H., Nagaso H., Kakui N., Ishikawa M., Hiranuma T., and Hoshiko S. Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-kappaB-dependent gene expression in primary cultured mouse glial cells. The Journal of Biological Chemistry 279 (2004) 42774-42786
10. Faraone-Mennella M.R., Gambacorta A., Nicolaus B., and Farina B. Immunochemical detection of ADP-ribosylating enzymes in the archaeon Sulfolobus solfataricus. FEBS Letters 378 (1996) 199-201
11. Pacifico F., and Leonardi A. NF-κB in solid tumors. Biochemical Pharmacology 72 (2006) 1142-1152
12. Woronicz J.D., Gao X., Cao Z., Rothe M., and Goeddel D.V. IκBkinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 278 (1997) 866-869
13. Yang J., and Richmond A. Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Research 61 (2001) 4901-4909
14. May M.J., Gao X., Cao Z., Rothe M., and Goeddel D.V. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 289 (2000) 1550-1554
15. Strickland I., and Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Annals of the Rheumatic Disease 65 (2006) 75-82
16. Dasgupta S., Jana M., Zhou Y., Fung Y.K., Ghosh S., and Pahan K. Antineuroinflammatory effect of NF-κB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. Journal of Immunology 173 (2004) 1344-1354
17. D'Acquisto F., and Ianaro A. From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors. Current Opinion in Pharmacology 6 (2006) 387-392
18. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2 (2002) 301-310
19. Richardson P.G., Hideshima T., Mitsiades C., and Anderson K. Proteasome inhibition in hematologic malignancies. Annals of Medicine 36 (2004) 304-314
20. Nasr R., El-Sabban M.E., Karam J.A., Dbaibo G., Kfoury Y., Arnulf B., Lepelletier Y., Bex F., de Thé H., Hermine O., and Bazarbachi A. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 24 (2005) 419-430